Abstracts tagged "Anti-citrullinated Protein Autoantibodies (ACPAs)"

Abstract Number: 0761 • ACR Convergence 2020
Anti-Peptidylarginine Deaminase Antibodies in the Individuals with Arthralgia at Risk of Progression to Rheumatoid Arthritis
Nora Petrovská¹, Klára Prajzlerová¹, Ivana Půtová², Monika Gregová¹, Petra Hánová², Heřman Mann³, Karel Pavelka¹, Jiří Vencovský¹, Ladislav Šenolt¹ and Mária Filková¹, ¹Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ²Institute of Rheumatology, Prague, Czech Republic, ³Institute of Rheumatology, Prague, Czech Republic. Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: In order to identify the individuals at risk of imminent progression to rheumatoid arthritis (RA), EULAR has established a definition of clinically suspect arthralgia…
Abstract Number: 0763 • ACR Convergence 2020
Plasmatic Proteome in Individuals with Arthralgia at Risk of Developing Rheumatoid Arthritis
Klára Prajzlerová¹, Nora Petrovská¹, Monika Gregová¹, Jiří Baloun², Petra Hánová², Karel Pavelka¹, Jiří Vencovský¹, Ladislav Šenolt¹ and Mária Filková¹, ¹Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ²Institute of Rheumatology, Prague, Czech Republic
Background/Purpose: The presence of antibodies against citrullinated proteins (ACPA) significantly increases the risk of developing rheumatoid arthritis (RA). EULAR characterised individuals with arthralgia suspicious for…
Abstract Number: 0768 • ACR Convergence 2020
Dynamics of Follicular Helper T Cells Subsets in Rheumatoid Arthritis Patients Before and After Treatment
Paola Virginia Ferrero¹, Luisina Onofrio¹, Cristina del Valle Acosta¹, Estefania Raquel Zacca¹, Nicolas Eric Ponce², Eduardo Mussano¹, Ignacio Isaac Cadile¹, Laura Onetti¹, Marina Werner¹, Alicia Beatriz Costantino¹, Eva Virginia Acosta Rodriguez³ and Adriana Gruppi², ¹HOSPITAL NACIONAL DE CLINICAS, FACULTAD DE MEDICINA, UNIVERSIDAD NACIONAL DE CORDOBA, CORDOBA, Cordoba, Argentina, ²FACULTAD DE CIENCIAS QUIMICAS, UNIVERSIDAD NACIONAL DE CORDOBA. CENTRO DE INVESTIGACIONES EN BIOQUIMICA CLINICA E INMUNOLOGIA, CORDOBA, Cordoba, Argentina, ³FACULTAD DE CIENCIAS QUIMICAS, UNIVERSIDAD NACIONAL DE CORDOBA. CENTRO DE INVESTIGACIONES EN BIOQUIMICA CLINICA E INMUNOLOGIA, CORDOBA, Argentina
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic inflammatory disease characterized by the production of autoantibodies like rheumatoid factor and anti- citrullinated protein. CD4+ follicular helper T…
Abstract Number: 0769 • ACR Convergence 2020
Does the Autoantibody-Response Mature Between Presentation with Arthralgia and Development of Rheumatoid Arthritis? – a Longitudinal Serological Study
Fenne Wouters¹, Ellis Niemantsverdriet¹, Nazike Salioska¹, Annemarie Dorjée¹, René Toes¹ and Annette van der Helm - van Mil², ¹Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands
Background/Purpose: Auto-antibodies in rheumatoid arthritis (RA) are often present years before disease onset but their mere presence does not seem enough to induce RA. Several…
Abstract Number: 0772 • ACR Convergence 2020
Modification of THP-1 Cells with Malondialdehyde-Acetaldehyde Increases Cellular Calcium Load Rendering Cells Susceptible to Citrullination of Self-Proteins
Nozima Aripova¹, Michael Duryee¹, Xiarepati Tieliwaerdi¹, Xiaoting Jiang¹, Lynell Klassen², James O'Dell¹, Bryant England¹, Ted Mikuls¹ and Geoffrey Thiele¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Univerisity of Nebraska Medical Center, Omaha, NE
Background/Purpose: The post translational modification of self-proteins with malondialdehyde-acetaldehyde (MAA) has been shown to alter protein function and antibodies to MAA are increased in both…
Abstract Number: 0801 • ACR Convergence 2020
The Comparative Effectiveness of Abatacept versus TNF Inhibitors in Patients Who Are ACPA Positive and Have the Shared Epitope: Results from a US National Observational Study
Leslie Harrold¹, Keith Wittstock², Sheila Kelly², Xue Han², Joe Zhuo², Amy Schrader¹, Nicole Middaugh¹, Page Moore¹ and Vadim Khaychuk², ¹Corrona, LLC, Waltham, MA, ²Bristol-Myers Squibb Company, Princeton, NJ
Background/Purpose: The HLA-DRB1 shared epitope (SE) is associated with joint destruction in ACPA+ patients (pts) with RA.1 In the Early AMPLE trial, among ACPA+ pts…
Abstract Number: 0804 • ACR Convergence 2020
Factors That Influence Biological Survival in Rheumatoid Arthritis: Results of a Real-world Cohort from the Netherlands
Elise van Mulligen¹, Saad Ahmed¹, Angelique Weel², Mieke Hazes³, Annette van der Helm - van Mil⁴ and Pascal de Jong¹, ¹Erasmus MC, Rotterdam, Netherlands, ²Erasmus School of Health Policy & Management, Maasstad hospital, Erasmus MC, Rotterdam, Netherlands, ³Erasmus Medical Center, Rotterdam, Netherlands, ⁴Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands
Background/Purpose: Data on biological survival, stratified for discontinuation reasons, and predictors that influence survival time have not been explored extensively. Therefore, we aim to explore…
Abstract Number: 0824 • ACR Convergence 2020
The Comparative Effectiveness of Abatacept versus Tofacitinib After 6 Months of Treatment in Patients with RA Who Were Anti-citrullinated Protein Antibody Positive at Baseline: Results from a US National Observational Study
Leslie Harrold¹, Keith Wittstock², Sheila Kelly², Xue Han², Ying Shan¹, Page Moore¹, Lin Guo¹ and Vadim Khaychuk², ¹Corrona, LLC, Waltham, MA, ²Bristol-Myers Squibb Company, Princeton, NJ
Background/Purpose: Previous data from the Corrona RA registry, conducted in a US clinical practice setting, demonstrated that patients (pts) with RA who were ACPA+ had…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].